OHSU

IRB #

IRB00009512

Title

A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer

Principal Investigator

Jeremy Cetnar

Study Purpose

To compare the effectiveness of MK-3475 (study drug) versus docetaxel in adults with previously-treated non-small cell lung cancer (NSCLC)

Medical Condition(s)

NSCLC

Eligibility Criteria

1. Male or female at least 18 years or older
2. Confirmed diagnosis of NSCLC
3. Previously treated with platinum doublet for stage IIIB/IV recurrent disease
4. Have tumor tissue available to submit to sponsor for additional testing
5. Additional criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until disease progression, unacceptable side effects, or consent withdrawal

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Merck Sharp & Dhome Corp.

Recruitment End

12/31/2014

Compensation Provided

No


Go Back